Efficacy And Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results from the Keepsake 1 Study
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac607
Risankizumab (RZB) improves the signs and symptoms of PsA, with efficacy maintained through 52 weeks. Alongside the efficacy data, this analysis of KEEPsAKE 1 also evaluates the safety and tolerability profile of RZB.
This study supports the use of RZB in patients with active PsA who have inadequate response, intolerance or contraindication to csDMARDs. It was generally well tolerated, with a long-term safety profile remaining stable relative to week 24. KEEPsAKE 1 remains ongoing and will allow further assessment of long-term efficacy and safety in PsA.